# Innovative Eyewear Inc: overview

LUCY · Nasdaq · CIK 1808377 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lucy.md) · [Financials](/companies/lucy/financials.md) · [Filings](/companies/lucy/filings.md) · [Insiders](/companies/lucy/insiders.md)

Latest reported revenue: [$1.0m](/filings/0001829126-26-008847.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:Revenues, accession 0001829126-26-008847).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [254](/filings/0001829126-25-009128.md) | [691 d](/filings/0001829126-26-002695.md) | [455](/filings/0001829126-26-005226.md) | [579](/filings/0001829126-26-008847.md) | [668](/filings/0001829126-25-009128.md) | [960 d](/filings/0001829126-26-002695.md) | [774](/filings/0001829126-26-005226.md) | [1,011](/filings/0001829126-26-008847.md) |
| Gross margin | % | [23.4%](/filings/0001829126-25-009128.md) | [13.6% d](/filings/0001829126-26-002695.md) | [48.5%](/filings/0001829126-26-005226.md) | [(2.2%)](/filings/0001829126-26-008847.md) | [36.6%](/filings/0001829126-25-009128.md) | [12.0% d](/filings/0001829126-26-002695.md) | [22.7%](/filings/0001829126-26-005226.md) | [24.0%](/filings/0001829126-26-008847.md) |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [(678.5%)](/filings/0001829126-25-009128.md) | [(307.8%) d](/filings/0001829126-26-002695.md) | [(391.4%)](/filings/0001829126-26-005226.md) | [(363.6%)](/filings/0001829126-26-008847.md) | [(274.8%)](/filings/0001829126-25-009128.md) | [(194.8%) d](/filings/0001829126-26-002695.md) | [(298.5%)](/filings/0001829126-26-005226.md) | [(165.3%)](/filings/0001829126-26-008847.md) |
| Diluted EPS | $ per share | [(0.99)](/filings/0001829126-25-009128.md) | not reported | [(0.72)](/filings/0001829126-26-005226.md) | [(0.66)](/filings/0001829126-26-008847.md) | [(0.38)](/filings/0001829126-25-009128.md) | not reported | [(0.37)](/filings/0001829126-26-005226.md) | [(0.26)](/filings/0001829126-26-008847.md) |
| Free cash flow | $k | [(1,400) d](/filings/0001829126-25-009128.md) | [(1,970) d](/filings/0001829126-26-002695.md) | [(2,352)](/filings/0001829126-26-005226.md) | [(2,117) d](/filings/0001829126-26-008847.md) | [(1,512) d](/filings/0001829126-25-009128.md) | [(1,367) d](/filings/0001829126-26-002695.md) | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [691](/filings/0001829126-23-002253.md) | [660](/filings/0001829126-24-001847.md) | [1,152](/filings/0001829126-25-002025.md) | [1,636](/filings/0001829126-26-002695.md) | [2,662](/filings/0001829126-26-002695.md) |
| Gross margin | % | [21.5%](/filings/0001829126-23-002253.md) | [(8.5%)](/filings/0001829126-24-001847.md) | [(10.4%)](/filings/0001829126-25-002025.md) | [13.1%](/filings/0001829126-26-002695.md) | [21.3%](/filings/0001829126-26-002695.md) |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [(469.8%)](/filings/0001829126-23-002253.md) | [(861.2%)](/filings/0001829126-24-001847.md) | [(578.2%)](/filings/0001829126-25-002025.md) | [(474.6%)](/filings/0001829126-26-002695.md) | [(285.2%)](/filings/0001829126-26-002695.md) |
| Diluted EPS | $ per share | not reported | [(0.87)](/filings/0001829126-24-001847.md) | [(10.87)](/filings/0001829126-25-002025.md) | [(5.19)](/filings/0001829126-26-002695.md) | [(1.90)](/filings/0001829126-26-002695.md) |
| Free cash flow | $k | [(1,235)](/filings/0001829126-23-002253.md) | [(3,346)](/filings/0001829126-24-001847.md) | [(5,845)](/filings/0001829126-25-002025.md) | [(6,802)](/filings/0001829126-26-002695.md) | [(7,348)](/filings/0001829126-26-002695.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/lucy/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Cetera Investment Advisers](/funds/1666741.md) | 2026-06-30 | $450.3k | 577,350 |  | Added +77,350 |
| [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $32.0k | 40,996 |  | New +40,996 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $23.1k | 29,596 |  | New +29,596 |
| [KEYBANK NATIONAL ASSOCIATION/OH](/funds/1089877.md) | 2026-06-30 | $15.6k | 20,000 |  | Added +5,000 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $14.1k | 18,135 |  | Reduced −42,382 |
| [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $9.5k | 12,130 |  | New +12,130 |
| [Clear Street Group Inc.](/funds/1881567.md) | 2026-06-30 | $6.9k | 115,121 |  | Reduced −100 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $4.0k | 5,186 |  | New +5,186 |
| [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $2.7k | 3,469 |  | Added +1,710 |
| [BRAVE ASSET MANAGEMENT INC](/funds/1085867.md) | 2026-06-30 | $1.9k | 31,388 |  | Unchanged |

## Recent filings

[All 259 filings](/companies/lucy/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-15 | 20:05 ET | [8-K](/filings/0001829126-26-011182.md) | 3.01 Delisting notice | 0001829126-26-011182 |
| 2026-10-08 | 20:30 ET | [8-K](/filings/0001829126-26-010910.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001829126-26-010910 |
| 2026-10-05 | 13:50 ET | [DEF 14A](/filings/0001829126-26-010767.md) | Proxy statement, period 2026-11-16 | 0001829126-26-010767 |
| 2026-08-14 | 17:00 ET | [10-Q](/filings/0001829126-26-008847.md) | Quarterly report, period 2026-06-30 | 0001829126-26-008847 |
| 2026-07-23 | 21:25 ET | [S-1](/filings/0001829126-26-007808.md) | Registration statement | 0001829126-26-007808 |
| 2026-07-09 | 20:30 ET | [8-K](/filings/0001829126-26-007468.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001829126-26-007468 |
| 2026-05-14 | 20:00 ET | [10-Q](/filings/0001829126-26-005226.md) | Quarterly report, period 2026-03-31 | 0001829126-26-005226 |
| 2026-03-25 | 20:05 ET | [10-K](/filings/0001829126-26-002695.md) | Annual report, period 2025-12-31 | 0001829126-26-002695 |
| 2026-01-07 | 02:45 ET | [SCHEDULE 13D/A](/filings/0001376474-26-000025.md) | Ownership report, active investor, amended | 0001376474-26-000025 |
| 2026-01-07 | 21:35 ET | [8-K](/filings/0001829126-26-000089.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001829126-26-000089 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001829126-26-002695.md), filed Mar 25, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1808377
- Tickers: LUCY, LUCYW
- Exchange: Nasdaq
- SIC code: 3851 Ophthalmic Goods
- State of incorporation: FL
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.